Diagnostic Delay and Associated Clinical Features of Tuberculosis among Adult Patients with Acute Myeloid Leukemia in Doha, Qatar

Abstract

Background: Tuberculosis is currently the world's leading cause of death arising from a single infectious condition. While T cell mediated immunity is recognized to have a major contribution to tuberculosis activation, the present investigation confirmed that TB was more prevalent among patients with acute myeloid rather than lymphoid leukemia and such association was frequently overlooked. The primary objective of this study is to estimate the diagnostic delay of tuberculosis among patients with acute myeloid leukemia (AML) and compare it to the general population in Qatar. Secondary objective is to study the clinical and epidemiologic characteristics of tuberculosis in patients with AML. Methods: This is a retrospective study of tuberculosis cases diagnosed in subjects with AML during the period from January 2008 till December 2016. Results: Among 215 subjects with AML identified during the study period, 12 (5.58%) received the diagnosis of tuberculosis. The estimated incidence of tuberculosis among AML cases was 7.14 cases per 1000 per year. The mean delay in diagnosis of tuberculosis was 64.2 days (95% CI: 26.8 -101.5) and the median was 45 days (interquartile range; Q1 -Q3, 29.5 -97.5). Prolonged fever was the most common presentation (100% of cases). Parenchymal lung involvement was the most common radiologic abnormality (83.3% of cases). Three patients (25%) died and 8 patients completed 9 to 12 months of anti-tuberculous treatment with clinical and radiological remission. Conclusion: Infections caused by Mycobacterium tuberculosis are not How to cite this paper: El Omri, H., Taha, R., Ibrahim, W., Kassem, N., Szabados, L., El Sabah, H., Abid, F.B., Gamiel, A., Al Khinji, A., Szmeigielski, W., Hasan, S. and Al Hijji, I. (2018

The Prevalence of Mycobacterium tuberculosis Infection Among Cancer Patients Receiving Chemotherapy in a Tertiary Care Center

“…On the other hand, a meta-analysis supported that all types of cancer increased the risk of active TB infection, with variation in the cumulative incidence rate/100,000 population (CIR) stratified by cancer type and TB incidence, where the CIR in low TB incidence countries being highest in hematological malignancies (418/100,000 population), while that reported in solid cancers was 244/100,000 population [ 19 ]. One study done in Qatar concluded that among 215 subjects with acute myelocytic leukemia identified during the study period, 12 (5.58%) were diagnosed with TB, in comparison to our study which reported no cases in those with hematological malignancies [ 22 ]. This could be justified by the actual higher number of included solid tumor cases in this study compared to the cases with hematological malignancies.…”

Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma

“…21 In 2018, a study in Qatar found that approximately 5.58% of 215 patients with acute myelocytic leukemia were coinfected with TB. 22 It is also important to note that our patient was infected with COVID-19 before TB reactivation. The COVID-19 virus was found to lead to multiple histological damages to the lungs, and it could play a significant role in TB reactivation secondary to immunosuppression due to the use of corticosteroids as a course of treatment.…”

“…reported that patients with solid malignancies had a 4.5‐times higher risk of TB infection than healthy individuals 21 . In 2018, a study in Qatar found that approximately 5.58% of 215 patients with acute myelocytic leukemia were coinfected with TB 22 …”

“… 21 In 2018, a study in Qatar found that approximately 5.58% of 215 patients with acute myelocytic leukemia were coinfected with TB. 22 …”